drugset
drugset / Trial / NCT05896228

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228 ↗

Phase 2 Recruiting 30 enrolled Benjamin T Diamond, MD Bristol-Myers Squibb · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Timeline

Start
2024-02-20
Primary completion
2029-03-01
Completion
2031-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Iberdomide Small molecule 1 mg Oral
Subject Iberdomide Small molecule 1.3 mg Oral
Background Acetaminophen Small molecule 650 mg Oral
Background Carfilzomib Other / unclassified 56 mg/m2 Intravenous
Background Daratumumab Monoclonal antibody 16 mg/kg Subcutaneous
Background Daratumumab Monoclonal antibody 1800 mg Subcutaneous
Background Dexamethasone Small molecule 20 mg Oral
Background Diphenhydramine Unknown 25 mg Oral
Background Montelukast Other / unclassified 10 mg Oral

Indications

plasma cell myeloma